Stockholders' Equity (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 08, 2021 |
Feb. 02, 2021 |
Jan. 08, 2021 |
Jul. 14, 2020 |
Aug. 24, 2017 |
Jan. 04, 2013 |
Sep. 15, 2021 |
Aug. 31, 2021 |
Feb. 28, 2021 |
Jan. 29, 2021 |
Dec. 18, 2020 |
Jul. 28, 2020 |
Sep. 30, 2021 |
Dec. 31, 2020 |
Oct. 15, 2021 |
Jan. 31, 2021 |
Jan. 28, 2021 |
|
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Warrant exercise price (in Dollars per share) | $ 15.25 | $ 0.1 | $ 1,525 | ||||||||||||||
Precentage of underwriting rate | 7.00% | ||||||||||||||||
Precenge of gross proceeds | 3.50% | ||||||||||||||||
Registered direct offering, description | (i) an aggregate of 1,476,016 shares of Series E preferred stock, convertible into an aggregate of up to 295,203 shares of common stock, (ii) common stock purchase warrants to purchase up to an aggregate of 100,000 shares of common stock at an exercise price of $12.30 per share, subject to customary adjustments thereunder, which were exercisable immediately upon issuance and have a term of five years, and (iii) common stock purchase warrants to purchase up to an aggregate of 195,203 shares of common stock at an exercise price of $12.30 per share with a term of five and one-half (5.5) years first exercisable nine (6) months after issuance, subject to customary adjustments thereunder, for gross proceeds of $4,000,003, before deducting any offering expenses. The Company used the net proceeds from this offering for working capital and liability reduction purposes including additional term debt repayment. In February 2021, 1,476,016 shares of Series E preferred stock were converted into 295,203 shares of common stock. | ||||||||||||||||
Net proceeds | $ 7,350 | ||||||||||||||||
Common stock shares issued (in Shares) | 734,965 | ||||||||||||||||
Long-term stock incentive plan, description | The maximum aggregate number of shares of common stock that may be issued under the LTIP, including stock awards, stock issued to directors for serving on the Company’s board of directors, and stock appreciation rights, is limited to 10% of the shares of common stock outstanding on the first business or trading day of any fiscal year. At January 1, 2021, a maximum of 406,200 shares of common stock may be issued. As of September 30, 2021, 333,627 shares had been granted, leaving 72,573 available. | ||||||||||||||||
Aggregate stock options (in Shares) | 40,858 | ||||||||||||||||
Stock options exercise price (in Dollars per share) | $ 5.9 | ||||||||||||||||
Stock fair value | $ 80,456 | ||||||||||||||||
Employee bonus expense | 150,000 | ||||||||||||||||
Stock par value (in Dollars per share) | $ 0.001 | ||||||||||||||||
Warrant modification expense | $ 2,881,729 | ||||||||||||||||
Issuance of warrants (in Shares) | 246,914 | ||||||||||||||||
Purchase aggregate shares (in Shares) | 4,393,230 | ||||||||||||||||
Exercises price (in Dollars per share) | $ 6.88 | ||||||||||||||||
Weighted average remaining life | 4 years 9 months 18 days | ||||||||||||||||
Warrants expired shares (in Shares) | 86,072 | ||||||||||||||||
September 2021 Offering [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Description of aggregated shares | the Company sold an aggregate of (i) 2,788,750 shares of common stock, par value $0.001 per share (the “Common Stock”), which includes 363,750 shares of Common Stock issued upon the exercise of the underwriters’ over-allotment option (the “Shares”) and (ii) accompanying warrants to purchase up to an aggregate of 2,788,750 shares of Common Stock, at an exercise price of $4.95 per share, subject to certain adjustments, which includes additional warrants issued upon the exercise of the underwriter’s over-allotment option to purchase up to an additional 363,750 shares of common stock (the “Warrants”), at a combined public offering price of $4.95 per Share and accompanying Warrant. The Company granted the underwriters a 45-day option to purchase up to 363,750 additional Shares and additional Warrants to purchase up to an additional 363,750 shares of Common Stock, which the underwriters exercised, in full, at closing. | ||||||||||||||||
August 2021 Offering [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Discription of purchase agreement | the Company entered into a securities purchase agreement (the Purchase Agreement) with institutional accredited investors (the Investors) providing for an aggregate investment of $4,000,000 by the Investors for the issuance by the Company to them of (i) 1,333,333 shares of Series F Convertible Preferred Stock, par value $0.0001 per share, of the Company (the Series F Preferred Stock) convertible into shares of common stock, par value $0.001 per share, of the Company (the Common Stock) that are issuable from time to time upon conversion of such shares of Series F Preferred Stock (the Conversion Shares); (ii) warrants, with a term of five and a half (5.5) years exercisable after February 16, 2022, to purchase an aggregate of up to 666,667 shares of Common Stock (the Warrant Shares) at an exercise price of $7.80 per share. The securities were issued to the investors were exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder, based on representations made by the investors, their prior relationship with the Company, and the absence of any general solicitation. The Company used the net proceeds from this offering for working capital and liability reduction purposes. In the quarter ended September 30, 2021, 1,160,000 shares of Series F preferred stock were converted into 656,604 shares of common stock. On October 15, 2021, after shareholder and Board approval of the reverse stock split, the exercise price for the Warrants was adjusted to $4.95 per share, and is being retroactively reported in accordance with ASC 260-10-55-12, Restatement of EPS Data. See Note 7. | ||||||||||||||||
December 2020 Offering [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Registered direct offering, description | (i) an aggregate of 1,515,151 shares of Series D preferred stock, convertible into an aggregate of up to 303,030 shares of common stock, (ii) common stock purchase warrants to purchase up to an aggregate of 100,000 shares of common stock at an exercise price of $4.90 per share, subject to customary adjustments thereunder, which were exercisable immediately upon issuance and have a term of five years, and (iii) common stock purchase warrants to purchase up to an aggregate of 505,060 shares of common stock at an exercise price of $4.90 per share with a term of five and one-half (5.5) years first exercisable nine (6) months after issuance, subject to customary adjustments thereunder, for gross proceeds of $2,000,000, before deducting any offering expenses. The Company used the net proceeds from this offering for working capital, new product initiatives and other general corporate purposes. On December 21, 2020, 1,515,151 shares of Series D preferred stock were converted into 303,030 shares of common stock. | ||||||||||||||||
July 2020 Offering [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Registered direct offering, description | On July 14, 2020, the Company closed a registered direct offering of (i) an aggregate of 377,851 shares of the Company’s common stock, par value $0.001 per share; (ii) pre-funded warrants to purchase up to an aggregate of 73,497 shares of Common Stock at an exercise price of $0.01 $0.10 per share, subject to customary adjustments thereunder; (iii) registered warrants, with a term of five (5) years exercisable immediately upon issuance, to purchase an aggregate of up to 157,972 shares of Common Stock (at an exercise price of $5.00 per share, subject to customary adjustments thereunder; and (iv) unregistered warrants, with a term of five and one-half (5.5) years first exercisable nine (6) months after issuance, to purchase an aggregate of up to 375,000 shares of Common Stock at an exercise price of $6.50 per share, subject to customary adjustments thereunder, for gross proceeds of $1,864,528, before deducting any offering expenses. | ||||||||||||||||
2017 Stock Incentive Plan [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Common stock voting rights, description | The aggregate maximum number of shares of common stock (including shares underlying options) that may be issued under the 2017 SIP pursuant to awards of restricted shares or options will be limited to 10% of the outstanding shares of common stock, which calculation shall be made on the first (1st) business day of each new fiscal year; provided that for fiscal year 2017, 150,000 shares of common stock may be delivered to participants under the 2017 SIP. Thereafter, the 10% provision shall govern the 2017 SIP. | ||||||||||||||||
Warrant [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Warrant exercise price (in Dollars per share) | $ 3.956 | ||||||||||||||||
Proceeds received (in Shares) | 423,933 | ||||||||||||||||
Director [Member] | 2013 Long-Term Stock Incentive Plan [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Aggregate fair value | $ 80,000 | ||||||||||||||||
Non Executive Employees [Member] | 2017 Management Incentive Plan [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Aggregate fair value | 13,283 | ||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Groos proceeds | $ 12,500,000 | ||||||||||||||||
Warrant [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Original warrants exercisable shares of common stock (in Shares) | 246,914 | ||||||||||||||||
Series E convertible preferred stock and the warrants [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Deemed dividend from beneficial conversion feature | $ 1,480,801 | ||||||||||||||||
Series D convertible preferred stock and the warrants [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Deemed dividend from beneficial conversion feature | $ 758,922 | ||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||||||||||
Investor exercised | $ 1,969,136 | $ 500,000 |